Advancing vaccine-based immunotherapy in glioblastoma treatment.

ABSTRACT: Glioblastomas (GBMs) originate from glial cells and are characterized by aggressive growth and poor prognosis. Despite advances in surgical resection, complete elimination remains challenging, often leading to recurrence that is resistant to standard therapies. Immunotherapy and conventional treatments show promise in enhancing therapeutic outcomes across various cancers. Researchers continue to explore new treatments, particularly radiation, chemotherapy, and surgery; however, glioblastoma remains highly challenging, with only modest improvements in survival. Recent progress in immunotherapy, especially with tumor vaccines such as peptide-based and cell-based options (eg, dendritic cell vaccines), represents significant advancements despite the limitations observed in current clinical tri

SUBMITTER: Singh DD 

PROVIDER: S-EPMC12314604 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature